HUADONG MEDICINE(SZ:000963) 智通财经网·2025-08-11 14:29Core Viewpoint - Huadong Medicine (000963.SZ) has entered into an exclusive commercialization agreement with Jiangsu Weikail Pharmaceutical Technology Co., Ltd. for the oral formulation VC005, which is a second-generation JAK1 inhibitor aimed at treating autoimmune diseases [1][2] Group 1: Agreement Details - Huadong Medicine's subsidiary, Huadong Medicine (Hangzhou) Co., Ltd., will pay an upfront fee of 50 million RMB and up to 180 million RMB in milestone payments to Jiangsu Weikail for the commercialization rights of VC005 in mainland China [1] - The agreement officially took effect on August 8, 2025 [1] Group 2: Product Information - VC005 is a novel, potent, and highly selective oral JAK1 inhibitor, currently in clinical development for multiple autoimmune diseases including moderate to severe atopic dermatitis, ankylosing spondylitis, rheumatoid arthritis, and vitiligo [1] - The product has shown comparable efficacy to Upadacitinib in completed Phase II clinical trials for moderate to severe atopic dermatitis, with itch relief observed on the same day of administration [2] - VC005 is currently in Phase III clinical trials for moderate to severe atopic dermatitis and is preparing for Phase III trials for active ankylosing spondylitis [2] - The product has completed Phase Ib trials for rheumatoid arthritis and has received IND approval for non-segmental vitiligo, with Phase II trials set to commence [2] - A sustained-release formulation of VC005 is also under simultaneous development [2]